girk1  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Alomone Labs girk1
    Functional comparison of GIRK2a and GIRK2c in HEK cells. ( A ) Whole-cell currents (V hold = −70 mV) evoked by baclofen (100 μM) in HEK cells expressing GABA B R, <t>GIRK1,</t> and either GIRK2a (red) or GIRK2c (blue). No current was evoked by baclofen in cells expressing only GABA B R (control, black). Scale: 500 pA/10 s. ( B ) Summary of baclofen-induced, steady-state current densities (I baclofen , pA/pF) in HEK cells expressing GIRK1/GIRK2a or GIRK1/GIRK2c ( t 19 = 1.1, P = 0.29; n = 10–11/group). Individual data points are represented as small squares overlapping the relevant bar in the plot. ( C,D ) Activation ( t 19 = 1.5, P = 0.16) and deactivation ( t 16 = 0.4, P = 0.72) kinetics for baclofen-induced currents in HEK cells expressing GIRK1/GIRK2a or GIRK1/GIRK2c (n = 9–11/group). ( E ) Representative concentration-response experiment for a HEK cell expressing GABA B R and GIRK1/GIRK2c. Scale: 500 pA/10 s. ( F,G ) Summary of concentration-response experiments for baclofen-induced currents in HEK cells expressing GIRK1/GIRK2a or GIRK1/GIRK2c ( t 17 = 1.0, P = 0.32; n = 9–10/group). Currents were normalized to the response evoked by 100 μM baclofen in each experiment.
    Girk1, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/girk1/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    girk1 - by Bioz Stars, 2022-11
    93/100 stars

    Images

    1) Product Images from "GIRK2 splice variants and neuronal G protein-gated K+ channels: implications for channel function and behavior"

    Article Title: GIRK2 splice variants and neuronal G protein-gated K+ channels: implications for channel function and behavior

    Journal: Scientific Reports

    doi: 10.1038/s41598-017-01820-2

    Functional comparison of GIRK2a and GIRK2c in HEK cells. ( A ) Whole-cell currents (V hold = −70 mV) evoked by baclofen (100 μM) in HEK cells expressing GABA B R, GIRK1, and either GIRK2a (red) or GIRK2c (blue). No current was evoked by baclofen in cells expressing only GABA B R (control, black). Scale: 500 pA/10 s. ( B ) Summary of baclofen-induced, steady-state current densities (I baclofen , pA/pF) in HEK cells expressing GIRK1/GIRK2a or GIRK1/GIRK2c ( t 19 = 1.1, P = 0.29; n = 10–11/group). Individual data points are represented as small squares overlapping the relevant bar in the plot. ( C,D ) Activation ( t 19 = 1.5, P = 0.16) and deactivation ( t 16 = 0.4, P = 0.72) kinetics for baclofen-induced currents in HEK cells expressing GIRK1/GIRK2a or GIRK1/GIRK2c (n = 9–11/group). ( E ) Representative concentration-response experiment for a HEK cell expressing GABA B R and GIRK1/GIRK2c. Scale: 500 pA/10 s. ( F,G ) Summary of concentration-response experiments for baclofen-induced currents in HEK cells expressing GIRK1/GIRK2a or GIRK1/GIRK2c ( t 17 = 1.0, P = 0.32; n = 9–10/group). Currents were normalized to the response evoked by 100 μM baclofen in each experiment.
    Figure Legend Snippet: Functional comparison of GIRK2a and GIRK2c in HEK cells. ( A ) Whole-cell currents (V hold = −70 mV) evoked by baclofen (100 μM) in HEK cells expressing GABA B R, GIRK1, and either GIRK2a (red) or GIRK2c (blue). No current was evoked by baclofen in cells expressing only GABA B R (control, black). Scale: 500 pA/10 s. ( B ) Summary of baclofen-induced, steady-state current densities (I baclofen , pA/pF) in HEK cells expressing GIRK1/GIRK2a or GIRK1/GIRK2c ( t 19 = 1.1, P = 0.29; n = 10–11/group). Individual data points are represented as small squares overlapping the relevant bar in the plot. ( C,D ) Activation ( t 19 = 1.5, P = 0.16) and deactivation ( t 16 = 0.4, P = 0.72) kinetics for baclofen-induced currents in HEK cells expressing GIRK1/GIRK2a or GIRK1/GIRK2c (n = 9–11/group). ( E ) Representative concentration-response experiment for a HEK cell expressing GABA B R and GIRK1/GIRK2c. Scale: 500 pA/10 s. ( F,G ) Summary of concentration-response experiments for baclofen-induced currents in HEK cells expressing GIRK1/GIRK2a or GIRK1/GIRK2c ( t 17 = 1.0, P = 0.32; n = 9–10/group). Currents were normalized to the response evoked by 100 μM baclofen in each experiment.

    Techniques Used: Functional Assay, Expressing, Activation Assay, Concentration Assay

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95
    Alomone Labs anti girk1 kir3 1 antibody
    Dampening D1R-MSNs activity improves social deficits in NAc-shShank3 mice (a) Representative image of <t>GIRK1</t> expression (green) in the NAc of Drd1a-dTomato (red) mice. (b) Experimental design. D1R-Cre positive (D1R:Cre + ) mice were injected in the NAc with AAV-hSyn-DIO-hM4Di-mCherry (DREADD) and after P60 whole-cell patch clamp recordings were performed. NAc slices were either pre-incubated with CNO and recorded in presence of CNO, or were incubated and recorded in aCSF only. (c) Number of action potentials (nAPs) across increasing depolarizing current steps (0-500 pA) in presence or absence of CNO. The number of APs was significantly decreased by the bath application of CNO (Repeated measures ANOVA, main effect of drug F (1, 11) = 6.060 p = 0.032, main effect of current steps F (10, 110) = 12.11 p
    Anti Girk1 Kir3 1 Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 95/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti girk1 kir3 1 antibody/product/Alomone Labs
    Average 95 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    anti girk1 kir3 1 antibody - by Bioz Stars, 2022-11
    95/100 stars
      Buy from Supplier

    93
    Alomone Labs guinea pig anti kv1 3 kcna3 extracellular antibody
    Comparison of stroke severity in WT versus <t>Kv1.3</t> −/− mice. (A) Infarct area and deficit score in 16‐week‐old WT ( n = 10) were compared to Kv1.3 −/− ( n = 14) male mice ( p
    Guinea Pig Anti Kv1 3 Kcna3 Extracellular Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/guinea pig anti kv1 3 kcna3 extracellular antibody/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    guinea pig anti kv1 3 kcna3 extracellular antibody - by Bioz Stars, 2022-11
    93/100 stars
      Buy from Supplier

    Image Search Results


    Dampening D1R-MSNs activity improves social deficits in NAc-shShank3 mice (a) Representative image of GIRK1 expression (green) in the NAc of Drd1a-dTomato (red) mice. (b) Experimental design. D1R-Cre positive (D1R:Cre + ) mice were injected in the NAc with AAV-hSyn-DIO-hM4Di-mCherry (DREADD) and after P60 whole-cell patch clamp recordings were performed. NAc slices were either pre-incubated with CNO and recorded in presence of CNO, or were incubated and recorded in aCSF only. (c) Number of action potentials (nAPs) across increasing depolarizing current steps (0-500 pA) in presence or absence of CNO. The number of APs was significantly decreased by the bath application of CNO (Repeated measures ANOVA, main effect of drug F (1, 11) = 6.060 p = 0.032, main effect of current steps F (10, 110) = 12.11 p

    Journal: bioRxiv

    Article Title: Inhibition of TRPV4 rescues circuit and social deficits unmasked by acute inflammatory response in a Shank3 mouse model of Autism

    doi: 10.1101/2021.10.13.464215

    Figure Lengend Snippet: Dampening D1R-MSNs activity improves social deficits in NAc-shShank3 mice (a) Representative image of GIRK1 expression (green) in the NAc of Drd1a-dTomato (red) mice. (b) Experimental design. D1R-Cre positive (D1R:Cre + ) mice were injected in the NAc with AAV-hSyn-DIO-hM4Di-mCherry (DREADD) and after P60 whole-cell patch clamp recordings were performed. NAc slices were either pre-incubated with CNO and recorded in presence of CNO, or were incubated and recorded in aCSF only. (c) Number of action potentials (nAPs) across increasing depolarizing current steps (0-500 pA) in presence or absence of CNO. The number of APs was significantly decreased by the bath application of CNO (Repeated measures ANOVA, main effect of drug F (1, 11) = 6.060 p = 0.032, main effect of current steps F (10, 110) = 12.11 p

    Article Snippet: Primary antibody used in this study: polyclonal rabbit anti-Kir3.1 (Girk1, 1/750 dilution, Alamone labs, APC-005).

    Techniques: Activity Assay, Mouse Assay, Expressing, Injection, Patch Clamp, Incubation

    Comparison of stroke severity in WT versus Kv1.3 −/− mice. (A) Infarct area and deficit score in 16‐week‐old WT ( n = 10) were compared to Kv1.3 −/− ( n = 14) male mice ( p

    Journal: Annals of Clinical and Translational Neurology

    Article Title: The potassium channel Kv1.3 as a therapeutic target for immunocytoprotection after reperfusion

    doi: 10.1002/acn3.51456

    Figure Lengend Snippet: Comparison of stroke severity in WT versus Kv1.3 −/− mice. (A) Infarct area and deficit score in 16‐week‐old WT ( n = 10) were compared to Kv1.3 −/− ( n = 14) male mice ( p

    Article Snippet: The immunofluorescence staining in Figure was performed with a polyclonal guinea pig anti‐Kv1.3 antibody (1:100, AGP‐005 from Alomone Labs) and the same polyclonal rabbit Iba‐1 (1;1000) and CD3 (1:250) antibodies listed above; Secondary Abs: Alexa Fluor® 546‐goat anti‐guinea pig IgG (1:1000, ab150185 from Abcam) and Alexa Fluor®488‐goat anti‐rabbit IgG (1:1500, ab150077 from Abcam).

    Techniques: Mouse Assay

    The Kv1.3 blocker PAP‐1 reduces infarction and improves neurological deficit in young and old WT female mice. (A) Infarct area and deficit score in vehicle ( n = 11) were compared to PAP‐1 (40 mg/kg; n = 15) treated 16‐week‐old female mice ( p = 0.007 for infarct, p = 0.016 for NES). (B) Infarct area and deficit score in vehicle ( n = 9) were compared to PAP‐1 (40 mg/kg; n = 9) treated 80‐week‐old female mice ( p = 0.032 for infarct, p = 0.003 for NES). Data are shown as whisker plots with data overlay. The boxes show mean ± SEM and the whiskers show confidence intervals.

    Journal: Annals of Clinical and Translational Neurology

    Article Title: The potassium channel Kv1.3 as a therapeutic target for immunocytoprotection after reperfusion

    doi: 10.1002/acn3.51456

    Figure Lengend Snippet: The Kv1.3 blocker PAP‐1 reduces infarction and improves neurological deficit in young and old WT female mice. (A) Infarct area and deficit score in vehicle ( n = 11) were compared to PAP‐1 (40 mg/kg; n = 15) treated 16‐week‐old female mice ( p = 0.007 for infarct, p = 0.016 for NES). (B) Infarct area and deficit score in vehicle ( n = 9) were compared to PAP‐1 (40 mg/kg; n = 9) treated 80‐week‐old female mice ( p = 0.032 for infarct, p = 0.003 for NES). Data are shown as whisker plots with data overlay. The boxes show mean ± SEM and the whiskers show confidence intervals.

    Article Snippet: The immunofluorescence staining in Figure was performed with a polyclonal guinea pig anti‐Kv1.3 antibody (1:100, AGP‐005 from Alomone Labs) and the same polyclonal rabbit Iba‐1 (1;1000) and CD3 (1:250) antibodies listed above; Secondary Abs: Alexa Fluor® 546‐goat anti‐guinea pig IgG (1:1000, ab150185 from Abcam) and Alexa Fluor®488‐goat anti‐rabbit IgG (1:1500, ab150077 from Abcam).

    Techniques: Mouse Assay, Whisker Assay

    Kv1.3 is expressed on microglia/macrophages and T cells in the infarct of an 80‐week‐old female mouse. (A) Sample immunofluorescence staining of 5‐ µ m thick paraffin sections from the 6‐mm slice of an 80‐week‐old female mouse on day 8 after tMCAO. (A) Kv1.3 staining colocalizes to Iba‐1 + cells. (B) Kv1.3 staining on smaller, CD3 + T cells (white arrowheads).

    Journal: Annals of Clinical and Translational Neurology

    Article Title: The potassium channel Kv1.3 as a therapeutic target for immunocytoprotection after reperfusion

    doi: 10.1002/acn3.51456

    Figure Lengend Snippet: Kv1.3 is expressed on microglia/macrophages and T cells in the infarct of an 80‐week‐old female mouse. (A) Sample immunofluorescence staining of 5‐ µ m thick paraffin sections from the 6‐mm slice of an 80‐week‐old female mouse on day 8 after tMCAO. (A) Kv1.3 staining colocalizes to Iba‐1 + cells. (B) Kv1.3 staining on smaller, CD3 + T cells (white arrowheads).

    Article Snippet: The immunofluorescence staining in Figure was performed with a polyclonal guinea pig anti‐Kv1.3 antibody (1:100, AGP‐005 from Alomone Labs) and the same polyclonal rabbit Iba‐1 (1;1000) and CD3 (1:250) antibodies listed above; Secondary Abs: Alexa Fluor® 546‐goat anti‐guinea pig IgG (1:1000, ab150185 from Abcam) and Alexa Fluor®488‐goat anti‐rabbit IgG (1:1500, ab150077 from Abcam).

    Techniques: Immunofluorescence, Staining

    PAP‐1 treatment and Kv1.3 deletion reduce Iba‐1 and CD3 staining in 80‐week‐old female mice. Serial paraffin sections (5 µ m thick) cut at 4 mm and the 6 mm from 80‐week‐old female mice were stained for Iba‐1 and CD3. (A) Percentage of Iba‐1‐positive pixels in the infarcted hemisphere. Vehicle‐treated WT ( n = 9), PAP‐1‐treated WT ( n = 9, p = 0.120 for 4‐mm section; p = 0.014 for 6‐mm section), and Kv1.3 −/− ( n = 18, p = 0.011 for 4‐mm section; p = 0.007 for 6‐mm section). (B) Percentage of CD3‐positive pixels in the infarcted hemisphere. Vehicle‐treated WT ( n = 9), PAP‐1‐treated WT ( n = 9, p = 0.049 for 4‐mm section; p = 0.027 for 6‐mm section), and Kv1.3 −/− ( n = 18, p

    Journal: Annals of Clinical and Translational Neurology

    Article Title: The potassium channel Kv1.3 as a therapeutic target for immunocytoprotection after reperfusion

    doi: 10.1002/acn3.51456

    Figure Lengend Snippet: PAP‐1 treatment and Kv1.3 deletion reduce Iba‐1 and CD3 staining in 80‐week‐old female mice. Serial paraffin sections (5 µ m thick) cut at 4 mm and the 6 mm from 80‐week‐old female mice were stained for Iba‐1 and CD3. (A) Percentage of Iba‐1‐positive pixels in the infarcted hemisphere. Vehicle‐treated WT ( n = 9), PAP‐1‐treated WT ( n = 9, p = 0.120 for 4‐mm section; p = 0.014 for 6‐mm section), and Kv1.3 −/− ( n = 18, p = 0.011 for 4‐mm section; p = 0.007 for 6‐mm section). (B) Percentage of CD3‐positive pixels in the infarcted hemisphere. Vehicle‐treated WT ( n = 9), PAP‐1‐treated WT ( n = 9, p = 0.049 for 4‐mm section; p = 0.027 for 6‐mm section), and Kv1.3 −/− ( n = 18, p

    Article Snippet: The immunofluorescence staining in Figure was performed with a polyclonal guinea pig anti‐Kv1.3 antibody (1:100, AGP‐005 from Alomone Labs) and the same polyclonal rabbit Iba‐1 (1;1000) and CD3 (1:250) antibodies listed above; Secondary Abs: Alexa Fluor® 546‐goat anti‐guinea pig IgG (1:1000, ab150185 from Abcam) and Alexa Fluor®488‐goat anti‐rabbit IgG (1:1500, ab150077 from Abcam).

    Techniques: Staining, Mouse Assay